Association between statin use and cardiovascular mortality decline at the population level in the Netherlands 1994-2010

Bijlsma, M. J., Janssen, F., Bos, J. H. J., Kamphuisen, P. W., Vansteelandt, S. & Hak, E., Oct-2014, In : Pharmacoepidemiology and Drug Safety. 23, s1, p. 246-247 2 p.

Research output: Contribution to journalMeeting AbstractAcademic

Background: There is ongoing debate about the determinants of the decline in age-specific cardiovascular mortality that has occurred in many Western countries since 1970. Objectives: We assessed the contribution of statin use to the decline in cardiovascular mortality for the Netherlands over the period 1994-2010. Methods: We used aggregated mortality data from Statistics Netherlands for the Netherlands as a whole with ∼16 million inhabitants and prevalence of drug use in a representative drug dispensing database ( covering ∼ 500,000 persons annually. In the study population aged 50-83 years over the period 1994 to 2010, we assessed the association between prevalence of statin use with mortality rates from acute myocardial infarction (AMI, ICD9-code 410), other ischaemic heart disease (other IHD, ICD9-codes 411-414) and cerebrovascular disease (ICD9-code 430-438) using a generalized linear model. We controlled for age, sex, birth cohort, other cardiovascular drug use, and diabetes. Results: One additional statin user per 100 personyears in a half year period was associated with a decrease of 1.25% (95% CI: 0.93 to 1.53%) in the total number of individuals that would have died because of AMI in the same half year period. Corresponding figures were 0.93% (CI: 0.42 to 1.43%) for other IHD and 1.06% (CI: 0.70 to 1.42%) for cerebrovascular diseases. In absolute numbers, this meant that statin use was associated with a reduction of approximately 110 AMI deaths per 2.4 million person-years exposed to AMI mortality on average throughout the study period. Conclusions: Statin use appeared associated with a decrease in cardiovascular mortality. Despite limitations inherent to ecological studies, the study provides evidence that at the population level lipid-lowering drugs play an important role in decreasing national cardiovascular mortality rates.
Original languageEnglish
Pages (from-to)246-247
Number of pages2
JournalPharmacoepidemiology and Drug Safety
Issue numbers1
Publication statusPublished - Oct-2014


  • statin (protein), cardiovascular agent, antilipemic agent, cardiovascular mortality, population, Netherlands, pharmacoepidemiology, risk management, mortality, cerebrovascular disease, prevalence, human, drug use, diabetes mellitus, statistical model, data base, ischemic heart disease, acute heart infarction, death, statistics, IADB

ID: 14307309